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https://doi.org/10.1186/s12969-019-0383-9RESEARCH ARTICLE Open AccessEffectiveness of long-term infliximab use
and impact of treatment adherence on
disease control in refractory, non-infectious
pediatric uveitis
Virginia Miraldi Utz1,2*† , Sabrina Bulas1,2†, Sarah Lopper1,2, Matthew Fenchel3, Ting Sa3, Mitul Mehta4, Daniel Ash5,
Daniel J. Lovell6 and Adam H. Kaufman1,2,7Abstract
Background: Refractory non-infectious uveitis is a serious condition that leads to ocular complications and vision
loss and requires effective systemic treatment to control disease. The effectiveness of long-term infliximab [IFX] in
refractory non-infectious childhood uveitis and the impact of treatment adherence on disease control were
evaluated.
Methods: Retrospective, single-center study between December 2002 and April 2016 of 27 children with refractory
non-infectious uveitis [17 with juvenile idiopathic arthritis, JIA] treated with long-term IFX [9+ months]. Disease
activity was assessed prior to and while on IFX using the Standardization of Uveitis Nomenclature [SUN]. Number of
visits per year with active uveitis was analyzed by repeated measures logistic regression analysis from 2 years prior
to IFX initiation or from onset of uveitis until most recent visit on IFX. Incomplete treatment adherence was
assessed for each visit and defined as any deviance in corticosteroid use, prescribed infusion frequency, and/or
follow-up examination frequency.
Results: Primary outcomes were sustained uveitic and systemic disease control prior to and during IFX treatment
and the impact of incomplete adherence on uveitic disease control while on IFX. Secondary outcomes included
corticosteroid and glaucoma medication requirement, ocular complications and need for surgical intervention.
Mean age at IFX initiation was 10.4 ± 4.5 years; initial mean dose was 6.6 ± 2.2 mg/kg [and given at weeks 0, 2, 4
and q4 weeks thereafter for 93%]. Median duration on IFX was 35 [range 9–128] months. Prior to IFX, 14/27 patients
had failed adalimumab ± methotrexate [MTX]; 21/27 failed MTX. IFX led to uveitis control in 89% and arthritis
control in 76% (13/17). The odds ratio of having controlled disease after IFX was 4.1 (2.6, 6.4) compared to pre-
treatment visits. Topical corticosteroids and glaucoma medications were statistically decreased (p = 0.007 right eye
[OD], 0.003 left eye [OS] and p = 0.001 OD, p = 0.028 OS respectively). Incomplete adherence to treatment showed
10.3 times greater odds (7.1, 15.0) of having disease activity than full adherence.
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Conclusions: This study adds significantly to the IFX literature by documenting outstanding uveitis control with
long-term IFX treatment in non-infectious pediatric uveitis patients. Higher dosage and shorter interval were utilized
without adverse effects. Importantly, this is the first study, to our knowledge, to document the significant impact of
treatment adherence on uveitis control.
Keywords: Uveitis, Iridocyclitis, Iritis, Infliximab, Biologic response modifier, Treatment adherence,Background
Pediatric non-infectious uveitis [NIU] is an important
cause of visual morbidity in children, with prevalence in
the United States of 29/100,000 [1]. Ocular inflammation
can be associated with systemic disease, most commonly
Juvenile Idiopathic Arthritis [JIA] [1] or may be idio-
pathic. Vision loss from ocular complications such as
band keratopathy, synechiae, cataracts, glaucoma, cystoid
macular edema and hypotony occur in up to 75% of pa-
tients [2–5]. Visual acuity worse than 20/40 and 20/200
occurs in approximately 20 and 5% of patients respect-
ively even with advances in therapeutic options [6].
Therefore, timely diagnosis and initiation of an effective
management protocol are strongly indicated.
While local and systemic therapy with corticosteroids
may be utilized as initial treatment, ocular [7, 8] and sys-
temic [9] side effects of long-term administration warrant
early implementation of corticosteroid-sparing therapy to
improve visual outcomes [8, 10]. Most commonly, metho-
trexate is used as initial treatment in children, with re-
sponse rate ranging from 50 to 75% of patients [6, 11]. For
those who do not respond or incompletely respond, escal-
ation to a biologic response modifier such as the tumor ne-
crosis factor-alpha [TNF-α] inhibitors, adalimumab [ADA,
Humira™] and infliximab [IFX, Remicade™], is appropriate
to attempt to control disease activity [12–15].
Cytokines like TNF-α have been shown to play a role
in the pathogenesis of uveitis, as evidenced by elevated
TNF-α levels in the aqueous humor [16, 17]. IFX is a
chimeric human/murine monoclonal antibody to TNF-
α, that binds to free and membrane-bound forms and
initiates a conformational change that inhibits binding to
TNF receptors [18]. IFX has been used for pediatric uve-
itis for many years with variability in reported response
rates ranging from 0 to 100% [19–26], with average re-
sponse rate of 72% based on meta-analysis by Simonini
and colleagues in 2014 [26].
To successfully manage and to treat uveitis, frequent
appointments and complicated medication regimens are
often needed. Adherence to both treatment and follow-
up evaluations are paramount to treatment success of
uveitis [27, 28]. Children represent a vulnerable popula-
tion, and treatment success may largely depend on the
partnership between the caregivers and the clinicians to
promote adherence. Uveitis with or without JIA has thepotential to leave residual and permanent disability,
which has life-long consequences for these children.
One of the benefits of IFX is that the clinician can track
infusion administration. Therefore, understanding the
impact of adherence on treatment efficacy and disease
control is an important endeavor. In this study, we
evaluate the long-term use of IFX to sustain control of
inflammation and impact of treatment adherence in a
single center study of children with recalcitrant NIU.
The number of patients in this study is larger than rele-
vant publications in the literature.
Methods
Institutional review board approval was obtained, and
the study adhered to the Declaration of Helsinki. The
ophthalmology and rheumatology medical records of 43
children with pediatric non-infectious uveitis from De-
cember 30, 2002 and April 30, 2016 at Cincinnati Chil-
dren’s Hospital Medical Center [CCHMC] or Cincinnati
Eye Institute [CEI] were reviewed. Potential patients
were identified by ICD-9 and ICD-10 billing codes. Pa-
tients were included in the study if they had received
IFX treatment for a minimum of 9 months, had
complete ophthalmology and rheumatology records
available spanning ≥2 years prior to IFX treatment initi-
ation or from uveitis onset to the start of IFX treatment
if less than 2 years. Complete ophthalmology records in-
cluded all visit notes and examination findings and were
collected systematically via an IRB-approved data collec-
tion sheet for each patient.
Data collection
Information on all patients with non-infectious uveitis
treated with IFX was collected and managed in REDCap
[Research Electronic Data Capture] [29]. Data included
demographic information, ophthalmologic and rheuma-
tologic examinations, results of laboratory testing, sys-
temic diagnoses, all prior and current systemic
treatments, IFX dosage and frequency, treatment adher-
ence, ocular medications [dose and route of administra-
tion] prior to and during treatment with IFX (Additional
file 1: Table S1). The anatomic location and grading of
intraocular inflammation were in accordance with the
Standardization of Uveitis Nomenclature [SUN] Classifi-
cation Scale [30]. JIA was diagnosed by a pediatric
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sociations for Rheumatology [ILAR] classification criteria
[31]. Failure of prior systemic steroid-sparing therapy
was defined as persistent or worsening uveitis and/or
failure to wean ocular corticosteroids to ≤2 drops of
prednisolone acetate 1% [PA] daily and/or failure to con-
trol systemic disease. Incomplete adherence was defined
at each visit while on infliximab as 1) missed appoint-
ment without rescheduling within 2 weeks, 2) missed in-
fusion or rescheduled infusion outside the prescribed
dosing interval, and/or 3) self-reported incomplete ad-
herence to prescribed systemic or topical medication.
Non-adherence to follow-up appointments was assessed
by reviewing the follow-up recommended in the oph-
thalmologist’s last disposition relative to the next ap-
pointment visit date. Non-adherence to infusion was
determined reviewing the dates of each infusion proced-
ure within the electronic medical record. The use of sys-
temic medications such as methotrexate and topical
corticosteroids was self-reported. If the self-reported
treatment did not correspond to the prescribed fre-
quency (based on the last visit note) or patient/ family
admitted to missing dosages, this was considered incom-
plete adherence.
Outcome measures
The clinical examination prior to starting IFX was com-
pared to the most recent visit while on IFX and included
best-corrected visual acuity [BCVA], intraocular pressure
[IOP], ocular inflammation [30], and presence or ab-
sence of active arthritis when applicable. Ocular compli-
cations and surgical interventions prior to and while on
IFX were assessed. Complications included band kera-
topathy [BK], ocular hypertension [OHT], glaucoma, an-
terior and posterior synechiae, hypotony, and cystoid
macular edema [CME]. Complications were as defined
by Woreta et al. [5], with the exception of ocular hyper-
tension and glaucoma in which standard pediatric-
specific criteria were utilized [32]. The percent with ac-
tive arthritis and/or uveitis, weekly topical corticosteroid
burden, and glaucoma medication burden were evalu-
ated. For those on difluprednate, the dosages were con-
verted to prednisolone acetate 1% [PA] equivalent [2
drops PA = 1 drop difluprednate] [33]. We also calcu-
lated the percentage reaching ≤2 drops of PA [7] as well
as steroid-free remission defined as no systemic or local
corticosteroids for the duration of the follow-up period
[34]. IFX-related adverse events were evaluated.
In addition to pre- and most recent visit comparisons,
we sought to analyze longitudinal disease activity and
complications by documenting the following in each eye
for all visits 2 years prior to [or from the onset of uveitis
if < 2 years] until the most recent visit on IFX: uveitic
disease activity; corticosteroid use [route/dose/frequency];and glaucoma medication use. Adherence was evaluated
for each visit while on IFX. Active anterior segment in-
flammation corresponded to cell grade 0.5+ or higher or
vitreous haze > 1+ as described by SUN and/or described
by terms such as “active, worsening inflammation, or dis-
ease progression.” [30, 34] Controlled uveitis corre-
sponded to findings of < 0.5+ cell or descriptive terms
such as “quiet, quiescent, and no active inflammation.”
[34] Controlled uveitis was further subdivided into those
who were controlled on ≤2 drops of PA/day versus those
requiring > 2 drops PA/day.
Best-corrected visual acuity [BCVA] was converted to
logMAR [the logarithm of the minimal angle of reso-
lution or decimal-form of BCVA] was compared prior to
and at the most recent visit on IFX by a paired t-test.
Visits with active disease per year before and during IFX
treatment were compared via a repeated measures logis-
tic regression analysis. The effect of adherence on dis-
ease control for each clinical visit while on IFX was
calculated by a repeated measures logistic regression
analysis. Baseline and at most recent visit weekly topical
corticosteroid burden before and while on IFX were
compared using a paired t-test. We assessed topical
glaucoma medication use via Wilcoxon signed-rank ana-
lysis at baseline, defined as before or within six months
of IFX initiation, and during IFX use starting six months
into treatment. The six-month timeframe was selected
to allow adequate time for full effectiveness of IFX in
combination with being able to slowly taper topical ste-
roids and subsequently taper glaucoma medications ac-
cordingly. We utilized a Fischer’s exact test to evaluate
the significance of complications pre- and during inflixi-
mab. SAS 9.4M4 software was used for all analyses [SAS
Institute Inc., Cary, NC.] Significance for all tests was set
a priori at α = 0.05.Results
Demographic and baseline characteristics
A total of 27 [18 female] patients’ records were included
with a median follow-up time on IFX was 35months
[range 9–128]. Sixteen patients were excluded secondary
to IFX treatment duration < 9months [n = 9] or incom-
plete records [n = 7]. Demographic and baseline clinical
and disease characteristics of the patients are presented
in Table 1. Importantly, 52% [14] of patients had failed
standard weight-based dosing of ADA therapy either
with or without concomitant MTX for either joint or
ocular disease, and three of the patients had failed
weekly weight-based ADA treatment. Patients on aver-
age had 15 ± 8 [median 13] visits prior to IFX start date
and 22 ± 15 [median 16.5] visits while on IFX. Thirteen
patients had ≥2 years of follow-up prior to IFX initiation,
and 21 patients had ≥1 year of follow-up prior to IFX
Table 1 Demographics and Baseline Characteristics of Pediatric Patients Treated with Infliximab
Demographics and Clinical Characteristics Number of patients (% of population)
Female, n = 27 18 (67%)
Race, n = 27
Caucasian 22 (82%)
African-American 2 (7%)
Hispanic 2 (7%)
Asian 1 (4%)
Juvenile idiopathic arthritis, n = 17 17 (63%)
Extended Oligoarticular 3 (3 ANA+)
RF-negative, Polyarticular 11 (9 ANA+)
Enthesitis-related 1 (HLA-B27 +)
Juvenile psoriatic arthritis 1 (ANA+)
Undifferentiated 1 (ANA+)
Idiopathic 7 (26%)
Sarcoidosis 1 (4%)
HLA-B27-associated 1 (4%)
Other 1 (4%)
Serology, n = 27
ANA positive 14 (52%)
RF positive 0
HLA-B27 1 (4%)
HLA-B51a 1 (4%)
Uveitis Laterality, n = 27
Bilateral 23 (85%)
Unilateral 4 (15%)
Uveitis Location, n = 27
Anterior 19 (70%)
Intermediate 5 (19%)
Anterior Intermediate 2 (7%)
Panuveitis 1 (4%)
Age (Mos) of JIA Diagnosis (n = 17)
Ave ± SD (median)
43.6 ± 36.0 (23)
Age (Mos) of Uveitis Diagnosis (n = 27)
Ave ± SD (median)
86.5 ± 53.5 (76)
Duration of uveitis (Mos) prior to IFX start date, (n = 27) Ave ± SD (median) 39.6 ± 36.0 (22)
Follow-up Duration (Mos) on IFX, (n = 27) Ave ± SD (median) 41.6 ± 31.2 (35)
Previous Treatments prior to IFX Startb, n = 27
Methotrexate (MTX) 21 (78%)
Adalimumab (ADA)c 14 (52%)
Etanercept (ETN) 1 (4%)
Oral prednisone within 2 years prior to IFX start 7 (65%)
Indications for IFX
Active uveitis in ≥1 eye pre-IFX [n = 27] 19 (70%)
Active uveitis OR < 0.5+ cell, but > 2 drops PA 1% to control disease [n = 27] 24 (90%)
Active JIA (joint disease) [n = 17] 11 (65%)
aNot routinely tested
bNo patients were treated with cyclosporine or mycophenolate
cAdalimumab was dosed at 20 mg every other week for patients 15 kg to < 30 kg and 40mg for patients ≥30 kg. Three patients failed weekly weight-based
therapy of adalimumab
Abbreviations: Mos months, Ave average, SD standard deviation, PA 1% Prednisolone acetate 1%, MTX methotrexate, ADA adalimumab, IFX infliximab, RF
rheumatoid factor, ANA+ anti-nuclear antibody positivity
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Table 2 Ocular Complications Pre and During IFX Treatment
Follow-up, n = 27
Pre-IFX During IFX P-value
Band keratopathy 3 0 0.24
Cystoid Macular Edema 5 0 0.051
New cataract diagnosis 13 5 0.52
New glaucoma diagnosis 7 0 0.02
New glaucoma suspect diagnosis 11 0 0.003
Cataract Surgery 3 2a 1.00
Glaucoma Surgery 5 2b 0.42
aCataracts that required surgery while on IFX were present prior to IFX
initiation. In both patients, absolute control of inflammation off topical steroids
prior to cataract surgery was rationale for the decision to start IFX
bGlaucoma surgery was performed in one of these patients within a month of
starting IFX
Miraldi Utz et al. Pediatric Rheumatology           (2019) 17:79 Page 5 of 9start. Those with < 2 years of follow-up had onset of dis-
ease at or within the 2 years prior to IFX start.
Mean initial dosing of IFX was 6.6 ± 2.2 mg/kg [me-
dian = 6.2 mg/kg] dosed every 2 weeks for the first 4
weeks, and then every 4 weeks thereafter for 92.6% [n =
25] of the population. Dosing was increased in 6 [22.2%],
decreased in 10 [37.1%], and maintained in 11 [40.7%]
over the follow-up period based on treatment response.
Ten patients [37%] were on 10 mg/kg or more at some
point in the treatment interval. No biosimilars were uti-
lized. Twenty-six [96.3%] patients received concurrent
MTX treatment [0.5 ± 0.3 mg/kg [5–25mg] once
weekly, 65% subcutaneous and 35% oral route] with IFX
for at least a portion of the treatment interval; 78% were
on MTX before starting IFX and 19% started MTX after
beginning IFX treatment to prevent the development of
human anti-chimeric antibodies [HACAs]. One patient
was on concurrent treatment with leflunomide.
At the baseline slit lamp examination, 70% of patients
had active uveitis in at least one eye, with 59% [10/17] of
patients with active disease having an associated diagno-
sis of JIA. Of the 30% patients who were documented
“controlled” at baseline, 62.5% [5/8] were on > 2 drops
of PA/day. Active joint disease was the indication for
IFX for remaining three patients.
Disease activity
At the most recent visit, 52% (14/27) of patients had no
uveitis activity without topical steroids, and 89% (24/27)
of patients were controlled with ≤2 drops PA/day. Pro-
portion of patients with controlled uveitis increased
from 30% before IFX to 89% on IFX. Joint disease in the
JIA patients was controlled in 76%. Of those who failed
IFX for either uveitis, arthritis or both, common features
are a systemic association and development of HACAs
in three (Additional file 2: Table S2) Results from the lo-
gistic regression demonstrated that patients were 4.1
times more likely to have active ocular disease in one or
more eyes at any clinical visit before starting IFX com-
pared to while on IFX treatment [p < 0.001, CI: 2.6, 6.4].
Sub-group analysis of the 17 patients with JIA did not
yield statistically significant predictive results [p = 0.18,
CI 0.868, 2.099]. Patients who met the criteria for in-
complete adherence while on IFX were 10.3 times as
likely to have active disease at any visit compared to
those who were adherent to treatment and follow-up
[p < 0.0001, CI: 7.1, 15.0]. Ten patients adhered to all
treatments and visits, while 17 patients had evidence of
incomplete adherence identified at one or more visits.
Corticosteroid burden
At the baseline examination, 63% patients were on > 2
drops of PA/eye/day. After receiving IFX treatment for a
mean of 41.6 ± 31.2 months [median 35 months, range9–128 months], 89% of patients met the topical steroid
threshold of ≤2 drops PA/eye/day in both eyes and 59%
of patients had discontinued use of all topical drops at
the most recent visit and were in steroid-free remission.
The paired t-test showed a significant reduction in
weekly PA equivalent dosage equivalent [p = 0.007 OD,
p = 0.003 OS]. Seven patients required oral prednisone
within the 2 years prior to starting IFX. Two patients re-
ceived oral prednisone while on IFX: one for active joint
disease and the other for pars planitis. Seven patients re-
quired periocular steroids within the interval 2 years
prior to or from onset of uveitis to start date of IFX.
Two patients received periocular steroids while on IFX:
one at the time of cataract surgery for post-surgical in-
flammatory control and the second for retinal vasculitis.
Ocular complications
Mean visual acuity at baseline [OD: 0.2 ± 0.4, 20/32; OS:
0.1 ± 0.1, 20/24] and at the most recent visit [OD: 0.20 ±
0.5, 20/32; OS: 0.1 ± 0.2, 20/24] was not statistically dif-
ferent [p = 0.09 OD, p = 0.10 OS]. Complications at base-
line were present in a majority of patients (Table 2).
Cataracts developed in five patients [3 eyes OD, 5 eyes
OS] while on IFX, but none of these eyes required sur-
gery over the follow-up (see Additional file 3: Table S3).
Cataract surgery was required in two patients [7.4%] [3
eyes] while on IFX, but these cataracts were present
prior to IFX initiation in both patients and need for in-
flammatory control prior to cataract surgery was the ra-
tionale for beginning IFX for one patient. There were no
episodes of CME in any patient while on IFX.
Seven patients [26%, 14 eyes] had a diagnosis of glau-
coma and 11 patients [41%; 21 eyes] had a diagnosis of
glaucoma suspect based on the presence of ocular
hypertension. No patients developed glaucoma or had
ocular hypertension while on IFX, and this was statistically
significant [p = 0.02, p = 0.003 respectively] (Table 2).
Glaucoma surgery was performed on two patients with
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[< 3months]. Lastly, topical glaucoma medication burden
was significantly reduced while on IFX [p = 0.0013 OD
and p = 0.0278 OS].
Complications of IFX treatment
In our population, IFX was well-tolerated, with no cases
of severe adverse events or opportunistic infections over
the follow-up period, even in those on higher dosages.
Six patients [22.2%] experienced side effects of IFX treat-
ment, four of whom developed HACAs. In two of the
four patients who developed HACAs, uveitic disease
and/or joint disease became uncontrolled, leading to dis-
continuation of IFX. One patient had a hypotensive epi-
sode with transfusion leading to discontinuation,
although this patient’s ocular disease was controlled at
the most recent visit. The four patients who developed
HACAs were treated subsequently with the following:
patient 1: abatacept followed by tocilizumab; patient 2:
ADA 40mg weekly (ADA naïve); patient 3: ADA weekly,
followed by abatacept and subsequently tocilizumab; and
the fourth patient was lost to follow-up. The remaining
two experienced headaches during an infusion but did
not discontinue IFX. Demographics and clinical charac-
teristics of those who failed infliximab treatment can be
found in Additional file 2: Table S2.
Discussion
IFX has a long track record of efficacy for treating
pediatric uveitis [19–26], however, several key findings
can be learned from this study: [1] IFX was efficacious
for long-term control of disease in the majority of this
population and represented a viable alternative for those
who had failed treatment with ADA for either uveitis
and/or joint disease; [2] Topical corticosteroid and glau-
coma medication was reduced on IFX; [3] Treatment ad-
herence is key to achieving optimal effectiveness.
Firstly, we found a high level of IFX effectiveness in
our patient population. Twelve of the 14 patients who
failed ADA treatment prior to IFX had active uveitis or
required > 2 drops of PA/day to control disease. After
changing to IFX, all but one patient was controlled at
their most recent visit and all had a steroid regimen of
≤2 drops of PA/day with half of the patients discontinu-
ing ocular steroids entirely. This study did not directly
compare efficacy of ADA to IFX; however, this study
supports previous studies that changing TNF-alpha in-
hibitors represents a viable option for those failing ADA
as initial treatment [35].
Significant variability of IFX response rate for pediatric
uveitis is present in the literature ranging from 0 to
100% [19–26, 36–39], with average of response rate of
72% based on a meta-analysis by Simonini and col-
leagues in 2014 [26]. Historically, the frequency anddosage has been variable for uveitis extrapolating from
the treatment of other autoimmune disorders such as
rheumatoid arthritis and inflammatory bowel disease, in
which dosages of 3–5 mg/kg dosed every 6 to 12 weeks
are adequate to control disease [40–43]. Several pediatric
uveitis studies that report less favorable results and/or
loss of effectiveness with IFX dosed at 5 mg/kg dose
every 6–8 weeks after initial q2week loading doses [20,
36–38]. Previous literature suggests that higher dosages
of IFX at an infusion frequency of every 4 weeks may be
needed to effectively control pediatric uveitis [22, 39].
Higher concentrations may allow more adequate pene-
tration of the ocular compartment as compared to joint
or gastrointestinal system. The pharmacokinetic and
pharmacodynamic aspects of biologic response modifiers
are complex and individualized optimal dosing predic-
tions have only been determined for inflammatory bowel
disease [44, 45]. For non-infectious pediatric uveitis, op-
timal dosing of IFX and treatment interval has been de-
termined empirically. A well-designed prospective trial
may help to guide patient-specific dosing for non-
infectious uveitis based on pharmacokinetic and phar-
macodynamic parameters.
Importantly, no severe adverse events occurred in the
present study. The frequency of HACAs in our popula-
tion [15%] was less than that observed in prospective
pediatric cohorts with JIA with or without uveitis [23–
37%] reported previously [46, 47]. The lower frequency
observed is likely an underestimate as HACAs were
measured only in those failing therapy. Alternatively,
higher and more frequent dosing used to treat uveitis
may be protective against antibody formation as demon-
strated by Aeschilmann and colleagues [46]. The routine
use of methotrexate or other DMARDs while on an IFX
may also prevent antibody formation. Randomized pro-
tocols combined with routine serum IFX levels and
HACAs are needed to delineate the role of dosage and
frequency of IFX and use of concomitant DMARDs in
preventing HACA formation.
Secondly, there were relatively few ocular complica-
tions and surgical interventions in our patients during
IFX treatment: no patients developed band keratopathy,
CME or new diagnoses of glaucoma suspect or glaucoma
while on IFX. The two patients’ cataracts that required
surgery while on IFX were already present prior to the
initiation of IFX, and IFX was utilized to control disease
prior to the indicated surgery. Likewise, one of the pa-
tients who required glaucoma surgery while on IFX had
surgery within 3 months of starting IFX. The high rate
of inflammatory control and low incidence of complica-
tions provides further support for IFX effectiveness at
this dosing and frequency.
Coinciding with decreased incidence of ocular compli-
cations, IFX treatment minimized known detrimental
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such as OHT, glaucoma, and cataract development [3–6,
9]. Although some patients were “quiet” and/or “con-
trolled” at baseline, the high steroid burden required to
control disease represented an insufficient long-term
treatment plan, as patients on chronically high doses of
topical corticosteroids are more likely to suffer compli-
cations [7, 48]. In order to capture the effectiveness of
IFX in patients who had quiet disease at baseline due to
aggressive topical and systemic treatment regimens, we
utilized steroid burden [drug, potency, dose, and fre-
quency] as a measurement marker. All of the patients
who were controlled at the most recent visit on IFX
were on ≤2 drops of PA, and a majority were in steroid-
free remission. Interestingly, glaucoma medication paral-
leled the reduction in corticosteroids, likely reflecting
resolution of ocular hypertension associated with re-
duced chronic corticosteroid use [48]. The reduction in
topical corticosteroid therapy further supports long-term
control on IFX compared to baseline.
Finally, this is the first study to our knowledge that as-
sesses the impact of treatment adherence on disease ac-
tivity in children with uveitis. Patients had a 10.4-fold
increased risk of having active disease with incomplete
adherence documented at any given visit while on IFX.
Treatment adherence as defined by the World Health
Organization is a “patient-centered term” describing “the
extent to which a person’s behavior – taking medication,
following a diet, and/or executing lifestyle, corresponds
with the agreed recommendations from a health care
provider” [49]. Treatment adherence has been exten-
sively studied in the adult population, most notably for
patients treated for primary open angle glaucoma [50–
53]. For example, in the adult glaucoma literature, sim-
plified dosing regimens and/or decreased frequency of
dosing has been shown to improve reports of adherence
[54, 55]. Likewise, recommendations have been proposed
to increase adherence in the adult population with uve-
itis [28]. However, risk factors and interventions for in-
complete treatment adherence have not been rigorously
studied in children with uveitis.
Children represent a unique population: parents or
guardians schedule and transport children to ap-
pointments and/or infusions, and treatments often
depend on parents to administer medications at
home in most cases. Adherence may be even more
difficult to discern in older children or teenagers
who self-administer drops or treatment, where ad-
herence is a shared responsibility. The asymptomatic
nature of JIA-like chronic iridocyclitis in which in-
flammation may be indolent and effects of damage
may not be appreciated until the disease advances
further, complicates treatment adherence. Therefore,
further research is clearly needed to determine therisk factors for incomplete treatment adherence and
barriers to adherence in children with uveitis. To ad-
dress incomplete adherence, a multi-disciplinary ap-
proach that includes a pediatric rheumatologist and
ophthalmologist combined with a social worker, de-
voted nurse and/or behavioral psychologist may
prove beneficial. Some considerations include efforts
in education of the disease process and conse-
quences, reducing appointment burden by consoli-
dating appointments/infusions, simplifying treatment
protocols and uniform instructions and/or charts to
document medication administration. Further re-
search in this area will help to define risk factors
and implement effective strategies to improve
adherence.
Strengths of this study include patient numbers and
longitudinal follow-up at a single center for biologic
medication management and evaluation of adherence on
treatment effectiveness. Because of previous reports of
initial control on IFX with waning effectiveness with
long-term follow-up [36–38], we selected patients who
had long-term follow-up of nine months or more. The
long mean duration of follow-up is another strength of
this study. A maintained response was observed in a vast
majority of patients over the treatment interval. We did
not include patients with short-term follow-up, as previ-
ous studies had demonstrated no difference between six
months on IFX and one year.
Limitations of this study include its retrospective na-
ture, heterogeneity of disease, and lack of a control
group. As a practice pattern at CCHMC, patients with
more severe disease tend to be placed on IFX as an ini-
tial TNF-alpha inhibitor since the high dose protocol
yields rapid control and confirmed adherence. Thus, the
successful outcomes in this study may actually be more
significant due to this practice. Additionally, success with
adherence may also be more significant in this group of
patients since the highly adherent regimen of IFX infu-
sions was used in patients that may have been selected
due to higher risk of poor adherence. One of the other
limitations to our statistical model was the variable ap-
pointment interval, which was based on disease activity.
Therefore, a patient may have more visits a specific year
compared to prior or future years. Likewise, in terms of
incomplete treatment adherence, missed IFX infusions
and doses of concurrent systemic therapy [i.e. MTX] have
delayed and/or variable effects of an unknown duration
on disease activity, and therefore the effects of interval in-
complete adherence for any particular office visit may not
by readily discernable for that specific visit. For example, a
patient may miss an IFX infusion and be quiet on next
follow-up, but then develop activity 2–3months later after
missing several doses. While side effects of IFX treatment
were minimal, long-term toxicity [10–15 years] cannot be
Miraldi Utz et al. Pediatric Rheumatology           (2019) 17:79 Page 8 of 9determined over the follow-up period. Larger, prospective
trials are needed to confirm and expand on these findings.
Conclusions
In conclusion, IFX is remarkably safe and effective for
long-term treatment of non-infectious pediatric uveitis.
Higher dosage and shorter intervals may be necessary to
achieve successful control in a greater percentage of pa-
tients. Corticosteroid burden, glaucoma medication bur-
den, and development of complications were reduced by
IFX treatment. Incomplete adherence greatly increased
the odds of having active disease while on IFX and fur-
ther quality improvement measures need to be studied
and implemented to improve adherence in this vulner-
able population.
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failed IFX for arthritis or uveitis are listed. As stated in the text, no major
trends were noted, however, a high proportion had associated systemic
disease. JIA = Juvenile idiopathic arthritis; ANA + = anti-nuclear antibody
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A = not applicable; HACAs = human antichimeric antibodies.
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complications per patient, please refer to Table 2. Abbreviations: OD –
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for the decision to start IFX. ** Glaucoma surgery was performed in one
of these patients within a month of starting IFX.
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